Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine
International Journal of Molecular Sciences · 22.07.2023 · 24 (14) · 11810
DOI: 10.3390/ijms241411810 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.07.2023. Verfasst von Piera Trionfini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy. Hauptthemen laut MEDLINE: Pluripotent Stem Cells, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Telethon Foundation, Roche (Italy), Fondazione Aiuti per la Ricerca sulle Malattie Rare (ARMR), Bergamo, Italy.
Abstract (Originalsprache)
Induced pluripotent stem cells (iPSC) have huge potential as cell therapy for various diseases, given their potential for unlimited self-renewal and capability to differentiate into a wide range of cell types. Although autologous iPSCs represents the ideal source for patient-tailored regenerative medicine, the high costs of the extensive and time-consuming production process and the impracticability for treating acute conditions hinder their use for broad applications. An allogeneic iPSC-based strategy may overcome these issues, but it carries the risk of triggering an immune response. So far, several approaches based on genome-editing techniques to silence human leukocyte antigen class I (HLA-I) or II (HLA-II) expression have been explored to overcome the immune rejection of allogeneic iPSCs. In this study, we employed the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9) system to delete the β2-Microglobulin (B2M) and the Class II Major Histocompatibility Complex Transactivator (CIITA) genes, essential for the correct surface expression of HLA-I and HLA-II proteins. The resulting hypoimmunogenic iPSC line has a normal karyotype, expresses the pluripotency stem cell markers, and is capable of differentiating into the three embryonic germ layers. Furthermore, we showed that it specifically retains the ability to differentiate towards different liver cells, such as endothelial-like cells, hepatocyte-like cells, and hepatic stellate-like cells. Our results indicate that hypoimmunogenic iPSCs could give a new cost-effective and off-the-shelf opportunity for cell therapy in liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 24126 Bergamo, Italy.
ORCID-Profile: Piera Trionfini, Marco Varinelli, Lorena Longaretti, Roberta Giampietro, Marta Todeschini, Giuseppe Remuzzi, Ariela Benigni, Susanna Tomasoni
Förderung
- Telethon Foundation
- Roche (Italy)
- Fondazione Aiuti per la Ricerca sulle Malattie Rare (ARMR), Bergamo, Italy
- Fondazione Telethon, Italy
- Fondazione ARMR
Zitieren
APA
Trionfini, P., Romano, E., Varinelli, M., Longaretti, L., Rizzo, P., Giampietro, R., Caroli, A., Aiello, S., Todeschini, M., Casiraghi, F., Remuzzi, G., Benigni, A., & Tomasoni, S. (2023). Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine. International Journal of Molecular Sciences, 24(14), 11810. https://doi.org/10.3390/ijms241411810
Vancouver
Trionfini P, Romano E, Varinelli M, Longaretti L, Rizzo P, Giampietro R, et al. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine. International Journal of Molecular Sciences. 2023;24(14):11810. doi:10.3390/ijms241411810
BibTeX
@article{Trionfini2023,
author = {Trionfini, Piera and Romano, Elena and Varinelli, Marco and Longaretti, Lorena and Rizzo, Paola and Giampietro, Roberta and Caroli, Annalina and Aiello, Sistiana and Todeschini, Marta and Casiraghi, Federica and Remuzzi, Giuseppe and Benigni, Ariela and Tomasoni, Susanna},
title = {Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {14},
pages = {11810},
doi = {10.3390/ijms241411810}
}
EUVIMED